Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Versicor Plans Anidulafungin Esophageal Candidiasis NDA

March 19, 2003

By Aaron Lorenzo

With positive Phase III data in hand, Versicor Inc. reiterated plans to file a new drug application by the end of next month for its lead candidate, anidulafungin. (BioWorld Today)

Versicor Plans Anidulafungin Esophageal Candidiasis NDA

March 19, 2003

By Aaron Lorenzo

With positive Phase III data in hand, Versicor Inc. reiterated plans to file a new drug application by the end of next month for its lead candidate, anidulafungin. (BioWorld Today)

Genta Gains $40M Credit Facility From Late-Stage Partner Aventis

March 18, 2003

By Aaron Lorenzo

Investors Waking Up To Hypnion; Company Closes $47.5M Series B

March 18, 2003

By Aaron Lorenzo

Investors Waking Up To Hypnion; Company Closes $47.5M Series B

March 18, 2003

By Aaron Lorenzo

Genta Gains $40M Credit Facility From Late-Stage Partner Aventis

March 18, 2003

By Aaron Lorenzo

Inspire Increases Share Amount, Raises $67.5M For Eye Products

March 17, 2003

By Aaron Lorenzo

Inspire Increases Share Amount, Raises $67.5M For Eye Products

March 17, 2003

By Aaron Lorenzo

Cytokine PharmaSciences Signs Baxter To MIF Technology Deal

March 14, 2003

By Aaron Lorenzo

Cytokine PharmaSciences Signs Baxter To MIF Technology Deal

March 14, 2003

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...